Sunday May 31, 2020

Will the $74bn Celgene deal be done before the market slows?

Deal would be largest pharmaceutical merger on record

6th January, 2019

Bristol-Myers Squibb has agreed to acquire Celgene Corp in a $74 billion deal that will unite two drug-makers battling for advantage in a crowded market for innovative cancer treatments.

Both companies have faced investor wariness about their prospects in recent months. Bristol makes an immunotherapy drug called Opdivo that accounts for roughly a quarter of its sales but that has trailed a rival medication from Merck & Co. Celgene, meanwhile, has been looking for a follow-up...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

The way we did business a few months ago may never return – so the opportunity is to make changes that will both aid recovery and set us up well for our new futures

Tom Maguire | 4 weeks ago

What’s coming up today and what you might have missed

Hannah O’Brien | 5 months ago